{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:23:13Z","timestamp":1783462993860,"version":"3.55.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Portuguesa de Cardiologia"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.repc.2025.08.007","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T16:03:43Z","timestamp":1764345823000},"page":"13-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world dapagliflozin treatment patterns in Portuguese patients with heart failure with reduced ejection fraction"],"prefix":"10.1016","volume":"45","author":[{"given":"Aurora","family":"Andrade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Teresa","family":"Tim\u00f3teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Oliveira Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1tima","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ot\u00edlia","family":"Sim\u00f5es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Pardal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rio","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Silva-Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.repc.2025.08.007_bib0110","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1002\/ehf2.14076","article-title":"Impact analysis of heart failure across European countries: an ESC-HFA position paper","volume":"9","author":"Rosano","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.repc.2025.08.007_bib0115","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2019-11-3","article-title":"DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure","volume":"9","author":"Kaplinsky","year":"2020","journal-title":"Drugs Context"},{"key":"10.1016\/j.repc.2025.08.007_bib0120","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1388-9842(02)00034-X","article-title":"Prevalence of chronic heart failure in Southwestern Europe: the EPICA study","volume":"4","author":"Ceia","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2025.08.007_bib0125","unstructured":"ESC 365 \u2013 Portuguese Heart Failure Prevalence Observational Study\/Estudo Observacional Portugues sobre Insuficiencia Card\u00edaca (PORTHOS). Available at: https:\/\/esc365.escardio.org\/presentation\/277288 [accessed 19 March 2025]."},{"key":"10.1016\/j.repc.2025.08.007_bib0130","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40256-017-0219-2","article-title":"Management of heart failure with preserved ejection fraction: current challenges and future directions","volume":"17","author":"Upadhya","year":"2017","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.repc.2025.08.007_bib0135","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.repc.2025.08.007_bib0140","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1093\/eurheartj\/ehac248","article-title":"An update on global epidemiology in heart failure","volume":"43","author":"Becher","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2025.08.007_bib0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.repc.2019.09.006","article-title":"Os custos da insufici\u00eancia card\u00edaca em Portugal e a sua evolu\u00e7\u00e3o previs\u00edvel com o envelhecimento da popula\u00e7\u00e3o","volume":"39","author":"Gouveia","year":"2020","journal-title":"Rev Port Cardiol"},{"key":"10.1016\/j.repc.2025.08.007_bib0150","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/ehf2.12399","article-title":"The current and future burden of heart failure in Portugal","volume":"6","author":"Gouveia","year":"2019","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.repc.2025.08.007_bib0155","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2025.08.007_bib0160","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ejhf.566","article-title":"European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions","volume":"18","author":"Crespo-Leiro","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2025.08.007_bib0165","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","article-title":"Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial","volume":"141","author":"Kosiborod","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2025.08.007_bib0170","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.repc.2025.08.007_bib0175","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1161\/CIRCULATIONAHA.119.044133","article-title":"Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF","volume":"141","author":"Martinez","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2025.08.007_bib0180","first-page":"E895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2025.08.007_bib0185","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2025.08.007_bib0190","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2025.08.007_bib0200","article-title":"Evaluating initiation and real-world tolerability of dapagliflozin for the management of HFrEF","author":"Tee","year":"2023","journal-title":"Br J Cardiol"},{"key":"10.1016\/j.repc.2025.08.007_bib0205","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jacc.2024.02.009","article-title":"Efficacy and safety of dapagliflozin in patients with acute heart failure","volume":"83","author":"Cox","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2025.08.007_bib0210","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.123.065254","article-title":"Dapagliflozin and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial","volume":"148","author":"Ostrominski","year":"2023","journal-title":"Circulation"}],"container-title":["Revista Portuguesa de Cardiologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255125003464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255125003464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T16:27:25Z","timestamp":1768667245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0870255125003464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0870255125003464"],"URL":"https:\/\/doi.org\/10.1016\/j.repc.2025.08.007","relation":{},"ISSN":["0870-2551"],"issn-type":[{"value":"0870-2551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world dapagliflozin treatment patterns in Portuguese patients with heart failure with reduced ejection fraction","name":"articletitle","label":"Article Title"},{"value":"Revista Portuguesa de Cardiologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.repc.2025.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}